The Underweight Overachiever: A Growth Story Nobody’s Asking For

The OTC Wonder Nobody’s Talking About

Sanofi Consumer Healthcare India Ltd (SANOFICONR) is the result of a demerger from Sanofi India Limited in 2023, extracting the entire over-the-counter (OTC) and consumer healthcare business into a standalone listed entity. Think Combiflam, Allegra, Avil, DePURA — brands your mother, grandmother, and probably her mother all know by name. The kind of household staples that don’t require quarterly guidance, quarterly conferences, or quarterly existential angst.

The company listed on September 13, 2024. That’s five months ago. The IPO came at ₹518/share. Today it sits at ₹4,410. The stock has climbed 850% in half a year. And somehow, analysts are calling it overvalued. Let that sink for a moment.

Then came the plot twist. On May 23, 2025, Clayton, Dubilier & Rice (CD&R), one of the largest independent PE firms globally, launched an open offer for 26% of the company at an undisclosed price. By June 2025, CD&R had acquired 10.88% (2.5 million shares) through the open offer, gaining a meaningful stake in what is, by every financial metric, one of India’s most efficient consumer healthcare engines.

Why would a PE firm spend billions on a company that just listed six months ago? Because the fundamentals are stupidly good. And because 152% ROCE doesn’t grow on trees. Let’s figure out what’s actually happening.

OTC Products. Household Names. Zero Product Innovation Needed.

Sanofi Consumer operates across three primary categories: pain management (Combiflam), allergy relief (Allegra, Avil), and essential vitamins (DePURA). These are not sexy businesses. They don’t have VC funding, they don’t have growth stories involving “ecosystems,” and they sure as hell don’t have metaverse angles. What they have is market share.

Combiflam owns approximately 6.3% of the pain relief category. Allegra commands 8.2% of allergy products. Avil has 2.5% of its segment. DePURA is at 1.5% for vitamin D. These aren’t Samsung market shares, but they’re meaningful slices of categories that India buys in bulk, year after year, with zero channel confusion.

The distribution story is the real moat. The company operates through independent distributors, stockists, pharmacy chains, and government institutions. Present in 29 Indian states plus 2 overseas markets. Combiflam sells at a rate of 117 strips per minute — meaning someone, somewhere in India is buying pain relief every five seconds. That’s not a business plan. That’s a printing press.

FY24 revenue split: 91% from product sales, 6% from services, 1% other operating revenue, 2% interest income. Exports account for just 9% of revenue, with 91% from domestic sales. A purely India-focused consumer healthcare play riding the back of aspirational middle-class healthcare spending and increasingly accessible pharmacy networks.

Q4 FY25: The Numbers That Break Excel